Biotoxtech Co. Ltd Total Assets
Biotoxtech Co. Ltd total assets. Based on the latest financial reports, Biotoxtech Co. Ltd (086040) holds total assets worth ₩130.06 Billion KRW (≈ $88.14 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Biotoxtech Co. Ltd for the company's overall valuation and market capitalisation.
Total Assets of Biotoxtech Co. Ltd (2011–2025)
Total assets of Biotoxtech Co. Ltd from 2011 to 2025. This chart illustrates how Biotoxtech Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Biotoxtech Co. Ltd (086040) share price today for real-time trading data and today's change.
Biotoxtech Co. Ltd - Asset Composition Analysis
Biotoxtech Co. Ltd Total Assets Breakdown (December 2025)
Biotoxtech Co. Ltd total assets breakdown as of December 2025. Biotoxtech Co. Ltd's total assets of ₩130.06 Billion consist of 36.9% current assets and 63.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 14.2% |
| Accounts Receivable | ₩8.70 Billion | 6.6% |
| Inventory | ₩7.22 Billion | 5.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.28 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Biotoxtech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 086040 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biotoxtech Co. Ltd's current assets represent 36.9% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 14.2% of total assets in 2025, up from 8.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Biotoxtech Co. Ltd Competitors by Total Assets
Key competitors of Biotoxtech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩167.98 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
Biotoxtech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 0.67 | 1.10 |
| Quick Ratio | 0.44 | 0.52 | 1.06 |
| Cash Ratio | 0.00 | 0.21 | 0.28 |
| Working Capital | ₩-41.32 Billion | ₩-27.06 Billion | ₩2.61 Billion |
Biotoxtech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Biotoxtech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | ₩131.61 Billion |
| Market Capitalization | $20.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biotoxtech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Biotoxtech Co. Ltd's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Biotoxtech Co. Ltd (2011–2025)
The table below shows the annual total assets of Biotoxtech Co. Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩131.61 Billion ≈ $89.19 Million |
-3.37% |
| 2024-12-31 | ₩136.19 Billion ≈ $92.29 Million |
-7.38% |
| 2023-12-31 | ₩147.04 Billion ≈ $99.64 Million |
+16.97% |
| 2022-12-31 | ₩125.70 Billion ≈ $85.19 Million |
+38.53% |
| 2021-12-31 | ₩90.74 Billion ≈ $61.49 Million |
+42.55% |
| 2020-12-31 | ₩63.65 Billion ≈ $43.14 Million |
+5.78% |
| 2019-12-31 | ₩60.18 Billion ≈ $40.78 Million |
-4.69% |
| 2018-12-31 | ₩63.14 Billion ≈ $42.79 Million |
+5.63% |
| 2017-12-31 | ₩59.77 Billion ≈ $40.51 Million |
+24.50% |
| 2016-12-31 | ₩48.01 Billion ≈ $32.53 Million |
+5.79% |
| 2015-12-31 | ₩45.38 Billion ≈ $30.75 Million |
-5.14% |
| 2014-12-31 | ₩47.84 Billion ≈ $32.42 Million |
+3.33% |
| 2013-12-31 | ₩46.29 Billion ≈ $31.37 Million |
+3.61% |
| 2012-12-31 | ₩44.68 Billion ≈ $30.28 Million |
+1.10% |
| 2011-12-31 | ₩44.19 Billion ≈ $29.95 Million |
-- |
About Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more